Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.

Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, Milanesi E, Ciorba A, Paris M, Facilissimo I, Macripò G, Clerico M, Ciuffreda L.

Clin Colorectal Cancer. 2008 Jan;7(1):48-54. doi: 10.3816/CCC.2008.n.007.

PMID:
18279577
2.

Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.

Buzaid AC, Mathias Cde C, Perazzo F, Simon SD, Fein L, Hidalgo J, Murad AM, Esser R, Senger S, Lerzo G.

Clin Colorectal Cancer. 2010 Dec;9(5):282-9. doi: 10.3816/CCC.2010.n.041.

PMID:
21208842
3.

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd.

J Clin Oncol. 2008 May 10;26(14):2311-9. doi: 10.1200/JCO.2007.13.1193. Epub 2008 Apr 7.

PMID:
18390971
4.

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.

Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G.

Br J Cancer. 2006 Mar 27;94(6):792-7.

5.

Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.

Ocvirk J, Cencelj S.

J Eur Acad Dermatol Venereol. 2010 Apr;24(4):453-9. doi: 10.1111/j.1468-3083.2009.03446.x. Epub 2009 Sep 27.

PMID:
19793151
6.

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.

Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH.

Ann Oncol. 2006 Mar;17(3):450-6. Epub 2005 Nov 22.

PMID:
16303861
7.

Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.

Mrabti H, De la Fouchardiere C, Desseigne F, Dussart S, Negrier S, Errihani H.

J Cancer Res Ther. 2009 Oct-Dec;5(4):272-6. doi: 10.4103/0973-1482.59907.

8.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E.

N Engl J Med. 2004 Jul 22;351(4):337-45.

9.

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F.

J Clin Oncol. 2012 Aug 10;30(23):2861-8. doi: 10.1200/JCO.2011.40.9243. Epub 2012 Jul 2.

PMID:
22753904
10.

Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).

Abdelwahab S, Azmy A, Abdel-Aziz H, Salim H, Mahmoud A.

J Cancer Res Clin Oncol. 2012 Sep;138(9):1487-92. doi: 10.1007/s00432-012-1229-8. Epub 2012 Apr 22.

PMID:
22526166
11.

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.

Zhang W, Gordon M, Lenz HJ.

Ann Med. 2006;38(8):545-51. Review.

PMID:
17438669
12.

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK.

J Clin Oncol. 2006 Oct 20;24(30):4914-21.

PMID:
17050875
13.

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX.

J Clin Oncol. 2007 Oct 10;25(29):4557-61. Epub 2007 Sep 17.

PMID:
17876013
14.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
15.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Jean GW, Shah SR.

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Review.

PMID:
18503402
16.

Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.

Venook AP.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S74-84. Review.

PMID:
19780248
17.

First-line single-agent cetuximab in patients with advanced colorectal cancer.

Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A.

Ann Oncol. 2008 Apr;19(4):711-6. Epub 2007 Dec 10.

PMID:
18073221
18.

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Vokes EE, Chu E.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Review.

PMID:
16736979
19.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

20.

Cetuximab: in the treatment of metastatic colorectal cancer.

Reynolds NA, Wagstaff AJ.

Drugs. 2004;64(1):109-18; discussion 119-121. Review.

PMID:
14723561

Supplemental Content

Support Center